13F-HR: Axon Enterprise Discloses $68M Cellebrite Stake

Axon Enterprise, Inc. has filed its Q3 2025 13F-HR report, revealing a significant holding of 3.68 million ordinary shares in Cellebrite DI Ltd valued at over $68 million.

Summary

• Axon Enterprise, Inc. filed a Form 13F-HR for the calendar quarter ended September 30, 2025.
• The report details Axon's institutional investment holdings, specifically a single entry.
• Axon holds 3,679,375 ordinary shares of Cellebrite DI Ltd (CUSIP: M2197Q107).
• The total market value of this holding is $68,178,819 as of September 30, 2025.
• Axon Enterprise, Inc. exercises sole investment discretion over these shares.
• The filing explicitly states zero sole, shared, or none voting authority for these shares, which is an unusual disclosure given sole investment discretion.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a standard regulatory disclosure of historical holdings. The unusual voting authority disclosure introduces a slight element of ambiguity but does not inherently indicate positive or negative sentiment for Axon's overall performance.

Positives

• The filing demonstrates transparency in Axon Enterprise, Inc.'s investment activities by disclosing its significant holding in Cellebrite DI Ltd.
• The substantial investment in Cellebrite DI Ltd could indicate strategic alignment or confidence in the digital intelligence sector.

Negatives

• The filing reports zero voting authority (sole, shared, or none) for the 3,679,375 shares of Cellebrite DI Ltd, despite Axon having sole investment discretion, which is an unusual and potentially ambiguous disclosure.

Risks

• The reported lack of voting authority for a significant holding in Cellebrite DI Ltd, despite sole investment discretion, could imply a reduced ability to influence corporate governance or strategic decisions at Cellebrite.
• The investment in a single issuer (Cellebrite DI Ltd) represents a concentration risk within Axon's disclosed holdings for this period.

Future Outlook

The Form 13F-HR is a historical disclosure of holdings and does not contain forward-looking statements or guidance from Axon Enterprise, Inc. regarding future investment strategies or performance.

Management Comments

• Isaiah Fields, Chief Legal Officer, signed the report on behalf of Axon Enterprise, Inc., representing that the information is true, correct, and complete.

Industry Context

This 13F filing provides insight into the investment activities of Axon Enterprise, Inc., an institutional investment manager. Such filings are crucial for market transparency, allowing investors to track the holdings of large institutional funds and potentially identify trends or significant positions in specific companies like Cellebrite DI Ltd, a leader in digital intelligence solutions.

Comparison to Industry Standards

• As a standard 13F-HR filing, the report adheres to regulatory requirements for disclosing institutional investment holdings.
• The disclosure of a single significant holding in Cellebrite DI Ltd by Axon Enterprise, Inc. is notable, as it indicates a focused investment rather than a broadly diversified portfolio for the reported period.
• The reported zero voting authority for a substantial holding, despite sole investment discretion, deviates from typical 13F disclosures where voting authority usually aligns with investment discretion, warranting further scrutiny compared to industry norms.

Stakeholder Impact

• Shareholders of Axon Enterprise, Inc. gain transparency into a portion of the company's investment portfolio, specifically its significant stake in Cellebrite DI Ltd.
• Shareholders of Cellebrite DI Ltd may view Axon's substantial investment as a vote of confidence, potentially influencing market perception and share price.
• Investment professionals and regulatory authorities can use this data to analyze institutional investment trends and compliance.

Next Steps

• Axon Enterprise, Inc. will be required to file its next Form 13F-HR for the quarter ending December 31, 2025, by February 14, 2026.

Key Dates

Keywords

Axon Enterprise, Cellebrite DI Ltd, 13F-HR, Institutional Holdings, Investment Management, Ordinary Shares, Digital Intelligence, SEC Filing